FDA Oversight Of Medical Products Remains A "High-Risk" Concern For GAO
This article was originally published in The Pink Sheet Daily
Executive Summary
Resource management and strategic planning, mounting challenges associated with globalization, oversight of post-market product safety, and the agency's efforts to address devices that are class III but continue to reach the market through the 510(k) pathway top GAO's list.